MedTrace Logo

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

NCT04770701 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-17

No results posted yet for this study

Summary

This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.

Conditions

Interventions

DRUG

Ahah Drug

\- Composition Ahah containing concentrated extracts of plants: Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.

DEVICE

Ahah Placebo

\- Composition Ahah (not containing concentrated extracts of plants): Eclipta prostrata 200mg, dioscorea cirrhosa 200mg, phyllanthus urinaria 150mg, adenosma glutinosum 150mg, impatiens balsamina 75mg and ascorbic acid 250mg) -Take 1tablet x 2 times / 24 hours. Maintained for 9 months.

Sponsors & Collaborators

  • Trieu, Nguyen Thi, M.D.

    lead INDIV

Principal Investigators

  • Tran Minh Duc, Dr. · Trieu, Nguyen Thi, M.D.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2021-01-08
Completion
2021-01-10
FDA Drug
Yes

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04770701 on ClinicalTrials.gov